anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Overdosage of nitroprusside can be manifested as excessive hypotension or cyanide toxicity (see WARNINGS) or as thiocyanate toxicity (see ADVERSE REACTIONS). The acute intravenous mean lethal doses (LD50) of nitroprusside in rabbits, dogs, mice, and rats are 2.8, 5.0, 8.4, and 11.2 mg/kg, respectively.

Treatment of cyanide toxicity: Cyanide levels can be measured by many laboratories, and blood-gas studies that can detect venous hyperoxemia or acidosis are widely available. Acidosis may not appear until more than an hour after the appearance of dangerous cyanide levels, and laboratory tests should not be awaited. Reasonable suspicion of cyanide toxicity is adequate grounds for initiation of treatment.

Treatment of cyanide toxicity consists of 

• discontinuing the administration of sodium nitroprusside;

• providing a buffer for cyanide by using sodium nitrite to convert as much hemoglobin into methemoglobin as the patient can safely tolerate; and then 

• infusing sodium thiosulfate in sufficient quantity to convert the cyanide into thiocyanate.

The necessary medications for this treatment are contained in commercially available Cyanide Antidote Kits. Alternatively, discrete stocks of medications can be used. Hemodialysis is ineffective in removal of cyanide, but it will eliminate most thiocyanate. Cyanide Antidote Kits contain both amyl nitrite and sodium nitrite for induction of methemoglobinemia. The amyl nitrite is supplied in the form of inhalant ampoules, for administration in environments where intravenous administration of sodium nitrite may be delayed. In a patient who already has a patent intravenous line, use of amyl nitrite confers no benefit that is not provided by infusion of sodium nitrite.

Sodium nitrite is available in a 3% solution, and 4 to 6 mg/kg (about 0.2 mL/kg) should be injected over 2 to 4 minutes. This dose can be expected to convert about 10% of the patient’s hemoglobin into methemoglobin; this level of methemoglobinemia is not associated with any important hazard of its own. The nitrite infusion may cause transient vasodilatation and hypotension, and this hypotension must, if it occurs, be routinely managed.

Immediately after infusion of the sodium nitrite, sodium thiosulfate should be infused. This agent is available in 10% and 25% solutions, and the recommended dose is 150 to 200 mg/kg; a typical adult dose is 50 mL of the 25% solution. Thiosulfate treatment of an acutely cyanide-toxic patient will raise thiocyanate levels, but not to a dangerous degree. The nitrite/thiosulfate regimen may be repeated, at half the original doses, after two hours.
PURPOSE:To obtain the titled drug preparation stable to heat and pressure, by adding one or more components selected from basic amino acids, cellulosic materials, casein, etc. as a stabilizer to kallidinogenase effective to cerebrovascular disorder, hypertension, etc., and forming the mixture in the form of a peroral preparation. CONSTITUTION:A kallidinogenase composition is prepared by compounding kallidinogenase with a stabilizer consisting of one or more compounds selected from basic amino acids, cellulosic materials, casein, hydrolyzed casein, gelatin and hydrolyzed gelatin, and spray-drying or freeze-drying the mixture. The composition is optionally added with a diluent (e.g. lactose, crystalline cellulose, etc.), and prepared in the form of a drug preparation. A stable drug can be prepared by the stabilizer without adding albumin which is a commonly used stabilizer. The amount of the stabilizer is preferably 0.005-40mg per 1 unit of kallidinogenase. The loss of the activity can be minimized even in the tableting process.
Compounds represented by the following general formula (I): (I) wherein each symbol is as defined in the description; salts thereof, solvates thereof or prodrugs thereof bind to DP receptors and antagonize the same. Therefore, they are useful in preventing and/or treating allergic diseases (allergic nephritis, allergic conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, etc.), systemic mast cell disease, systemic mast cell activation disorder, anaphylactic shock, airway contraction, urticaria, eczema, diseases with itching (atopic dermatitis, urticaria, etc.), secondary diseases (cataract, retinal separation, inflammation, infection, sleep disturbance, etc.) caused by behaviors associating itching (scratching, beating, etc.), inflammation, chronic obstructive pulmonary disease, ischemic reperfusion injury, cerebrovascular disorders, rheumatoid arthritis, pleuritis, ulcerative colitis and so on. Because of binding specifically to DP receptors but only weakly binding to other prostaglandin receptors, the above compounds enable the production of drugs having little side effects.
TECHNIQUE: (1) A four-pointed star-shaped incision was made to separate the skin around the stoma intestine. (2) The stoma intestine was resected, and side-to-side or end-to-side anastomosis was performed to restore the continuity of the intestine. (3) The peritoneum and rectus sheath should be closed using continuous full-thickness sutures. (4) The subcutaneous fat layer and dermis layer should be sutured using purse-string sutures. Two holes should be made in the center of the sutured area. (5) The cross should be sutured intermittently on all four sides using 1-2 stitches. (6) A rubber strip should be placed in the center of the small hole.
RESULTS: The presence of a small hole in the center of the incision and the use of a rubber strip for drainage facilitate early fluid drainage. The design of a cross-stitched skin incision helps reduce local tension.
CONCLUSION: The modified cross-suture technique may reduce postoperative incision infections and associated pain, which is a suitable incision treatment method for loop stoma reversal.
Objective: To identify efficacy and safety of pudendal nerve block in tubing through the third posterior sacral foramen for the treatment of pudendal neuralgia (PN). Methods: A retrospective study with 222 PN patients was conducted in the Department of Pain Management of Beijing Tsinghua Changgung Hospital from January 2020 to April 2023. These patients were divided into two groups based on their treatment methods: pudendal nerve block in tubing through the third posterior sacral foramen (observation group, n=101) and ultrasound-guided pudendal nerve block (control group, n=121). Primary outcome measure was the 90-day postoperative pain relief rate. Secondary outcome measures included visual analog scale (VAS) at 1, 7, 14, 30 and 90 d after surgery, the incidence of tramadol uses after surgery, postoperative self-rating anxiety scale (SAS) scores and the incidence of adverse events. Factors that influenced pain relief within 90 days after surgery were analyzed by using binary logistic regression analysis. Results: Observation group included 34 males and 67 females, aged (49.8±16.0) years old. Control group included 38 males and 83 females, aged (43.7±14.0) years old. The 90-day postoperative pain relief rate of the observation group patients was 38.6% (39/101), which was higher than the 24.0% (29/121) of the control group patients (P=0.018). Both the observation group and the control group showed an interaction effect of time and group after treatment for VAS scores (both P<0.05). In intra-group comparison, the VAS scores at 1, 7, 14, 30 and 90 d after treatment in both groups were lower than those before treatment (all P<0.05). In inter-group comparison, the differences of the VAS scores were not statistically significant in the observation group compared with those in the control group at 1, 7, 14, 30 and 90 d after surgery (all P>0.05). The SAS score of the observation group at 90 d after surgery was 51.5±6.2, which was lower than the 53.4±5.8 of the control group (P=0.022). There was no statistically significant difference in the incidence of postoperative tramadol uses and adverse events between the two groups (both P>0.05). Pudendal nerve block in tubing through the third posterior sacral foramen was a protective factor for pain postoperative relief in PN patients at 90 d after surgery (OR=1.92, 95%CI: 1.05-3.48, P=0.033). Conclusion: Pudendal nerve block in tubing through the third posterior sacral foramen is a safe and effective minimally invasive treatment. It has a higher postoperative pain relief rate within 90 d after surgery, without increasing the uses of postoperative rescue analgesics and the incidence of adverse events.
Hair brushes of synthetic material and other similar objects, e.g. combs, are cleaned by contacting with a soln of an oxidising or reducing agent which dissolves easily in water and is capable of dissolving or destroying tangled hair without simultaneously attacking the non-proteinaceous bristles, e.g. of nylon, also over long treatment periods, followed by removing object from soln. A Cl- contg. oxidising agent supplying 0.1-20 g/l Cl2 is pref. used, more pref. LiOCP, opt. mixed with 15.40 wt.% concn. and may be thioglycolates or KBH4. Cleaner may be used as tablets or powder packed in plastic lined Al foils.
FIELD: medicine, phytotherapy. SUBSTANCE: dried peony roots (Paeonia officinals) are extracted with distilled water as measured 50 ml of water per 1 g of raw, mixture is boiled in water bath, infused in darkness for 20-24 h at 37 C and precipitate is separated. Supernatant is brought about to initial volume, frozen and dried by lyophilization. Invention allows to obtain product exhibiting the broad spectrum of biological effect. EFFECT: improved method of preparing. 3 cl, 1 tbl
The present invention relates to novel therapeutic protein useful in the treatment of diseases, in particular in human subjects. The results of the inventor strongly support the use of soluble IL-18R.alpha. in the treatment of diseases such as autoimmune or demyelinating disease, in particular Multiple Sclerosis (MS). Accordingly, the invention provides soluble IL-18R.alpha. for use in the treatment of autoimmune or demyelinating disease, in particular MS.  The invention also provides methods of treating, preventing or ameliorating the symptoms of autoimmune or demyelinat ing disease, in particular MS, in a subject, preferably a human subject, by administering a therapeutically effective amount of said soluble IL-18R.alpha. to the subject.
The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 2.5x10\^6 MBCART2019.1 per kg BW in a single infusion and maximum 2 dose levels. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. If more than two DLTs are observed at dose level 1, trial will continue at dose level 0. Dose escalation continues until at least \>2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.
<P>PROBLEM TO BE SOLVED: To provide a one-part type hair dye not damaging skin surface and hair and utilizing stable optical energy.  <P>SOLUTION: This one-part type hair dye utilizing optical energy is characterized by compounding 0.3 to 5.0 wt.% of a silver salt (excluding silver halides) and 0.2 to 5.0 wt.% of one or more amino acids (excluding reducing amino acids such as cysteine and sulfur-containing amino acids such as methionine) with a hair dye cream base. The amino acids are preferably neutral amino acids, acidic amino acids, basic amino acids (excluding sulfur-containing amino acids and reducing amino acids such as cysteine). Especially preferable amino acids are arginine, histidine and lysine which are basic amino acids. PH is adjusted to 2 to 8 in these preparations. Dihydroxyacetone of 0.01 to 1.5% is compounded and the pH of the preparation is adjusted to 2 to 7 to obtain a one-part type hair dye utilizing optical energy.  <P>COPYRIGHT: (C)2007,JPO&INPIT
A composition for improved oral care includes fibrillated material and friction elements for removal of plaque biofilm, and additional ingredients useful in oral care compositions. The composition also may include particulate SuperAbsorbent Polymer, which may be surface cross-linked. Certain ingredients may be minimized or avoided to reduce the lubricity of the composition. The composition may be a viscoelastic fluid having a desired viscosity, yield stress and elastic modulus. The efficacy can be characterized by its removal of biofilm due to flow inside tubes. Also useful are standard rheological and tribological measurements. Also disclosed are apparatus for administering the composition, and methods.
This study will determine the MTD of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1 and will assess clinical tumor response to treatment. KK-LC-1 is an abnormal protein that is expressed by certain types of cancer. The cancers that most commonly express KK-LC-1 include gastric, lung, breast, and cervix cancer. KK-LC-1 TCR-T cells are autologous T cells that are genetically engineered to target the KK-LC-1 antigen. Tumor targeting by the KK-LC-1 TCR requires that subjects have the the HLA-A\*01:01 allele. Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. They will then receive a single infusion of KK-LC-1 TCR-T cells, which will be followed by administration of aldesleukin. Adverse events, dose limiting toxicity, tumor response, and tumor response duration will be determined.
In controlled clinical trials, rash (all grades, regardless of causality) occurred in approximately 20% of patients treated with REYATAZ. The median time to onset of rash in clinical studies was 7.3 weeks and the median duration of rash was 1.4 weeks. Rashes were generally mild-to-moderate maculopapular skin eruptions. Treatment-emergent adverse reactions of moderate or severe rash (occurring at a rate of ≥2%) are presented for the individual clinical studies [see Adverse Reactions (6.1)]. Dosing with REYATAZ was often continued without interruption in patients who developed rash. The discontinuation rate for rash in clinical trials was <1%. Cases of Stevens-Johnson syndrome, erythema multiforme, and toxic skin eruptions, including drug rash, eosinophilia, and systemic symptoms (DRESS) syndrome, have been reported in patients receiving REYATAZ. [See Contraindications (4) and Adverse Reactions (6.1).] REYATAZ should be discontinued if severe rash develops.
Questionnaires, Mechanical Temporal Summation assessment and pain threshold assessment will be assigned to patient. Within this cohort, some patients will have high pain score recorded (persistent pain) during the follow-up evaluations at 4 and 6 months.
EU Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
FIELD: medicine.SUBSTANCE: method involves a preclinical electroneuromyography (ENMG) of the neuromuscular apparatus of injured and intact lower extremities to measure a muscle response amplitude - an M-response. The findings are recorded. Starting from the second postoperative day, in the course of the drug-induced neuroprotective treatment and therapeutic exercises, the following therapy is additionally performed for 10-15 days. If the injured M-response amplitude is below 4.0 mV, while the respective intact value is more than 4.0 mV, the anti-inflammatory physical treatment covering the injured extremity is performed. If the injured M-response amplitude is more than 4.0 mV, while the respective intact value is below 4.0 mV, the stimulating passive physical treatment covering the intact extremity is performed. If the M-response amplitude of the injured and intact extremities is below 4.0 mV, the anti-inflammatory physical treatment covering the injured extremity and the stimulating passive physical treatment covering the intact extremity are performed. Three and six months following the surgical management, the repeated ENMG of the neuromuscular apparatus of the lower extremities to measure the M-response amplitude. If observing the preserving M-response amplitude below 4.0 mV on at least one lower extremity three months following the surgical management, the repeated complex of the drug-induced neuroprotective treatment and the stimulating passive physical treatment covering the neuromuscular apparatus of the hip with the M-response amplitude below 4.0 mV are performed. If observing the preserving M-response amplitude below 4.0 mV on at least one lower extremity six months following the surgical management, the repeated complex of the drug-induced neuroprotective treatment and the stimulating passive physical functional treatment covering the neuromuscular apparatus of the hip with the M-response amplitude below 4.0 mV are performed by walking electrical stimulation of the hip and shin.EFFECT: method reduces the length of treatment and increases its effectiveness with decreasing a percentage of neurological complications by performing the individual complex exposure on the neuromuscular apparatus of the lower extremities taking into account the ENMG findings of the neuromuscular apparatus of the lower extremities.2 cl, 3 ex
Couples will have three MI sessions over a 60-day period. These sessions will focus on communication between the couple, alcohol consumption patterns, and setting goals for alcohol-use reduction.
Patients receive ruxolitinib PO BID and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of ruxolitinib and venetoclax at the discretion of the sponsor-investigator.
Abstract A method of immunotherapy to treat cancer or a synergistic anti-cancer treatment by administering an effective amount of a natural cytokine mixture (NCM), an effective amount of cyclophosphamide (CY), or an effective amount of indomethacin (INDO), wherein the NCM, CY, or INDO are administered singly or in communications thereof. An anti-metastatic treatment method by promoting differentiation and maturation of immature dendritic cells in a lymph node; allowing presentation thereof; and preventing development of metastasis. A method of using an NCM as a diagnostic skin test for predicting treatment outcome. A method of pre-treating dendritic cells (DC) and a method of treating monocyte defects characterized by sinus histocytosis or a negative NCM skin test. Compositions and methods for eliciting an immune response to endogenous or exogenous tumor antigens. 3 NODE 51ZE CONTROLS C H&N SCC g H&NScC E - IRX-2
The invention relates to new application of a traditional Chinese medicine preparation, namely application of Jiu Wei Shuang Jie Kou Fu Ye to prepare drug for treating chronic hepatitis. The Jiu Wei Shuang Jie Kou Fu Ye is composed of raw materials medicines comprising, by weight, 333.5 g of Chinese thorowax roots, 233.5 g of cooked rhubarb, 333.5 g of artemisia annua, 133.0 g of honeysuckle, 233.5 g of wine moxibustion scutellaria baicalensis, 256.5 g of folium isatidis, 233.5 g of dandelions, 133.0 g of Paris polyphylla and 100.0 g of peeled amomum tsaoko prepared with ginger. A preparation method is not changed. The Jiu Wei Shuang Jie Kou Fu Ye has a curative effect on the chronic hepatitis disease. According to the usage and the dosage of the Jiu Wei Shuang Jie Kou Fu Ye, a user orally takes 30 ml of Jiu Wei Shuang Jie Kou Fu Ye every time and takes Jiu Wei Shuang Jie Kou Fu Ye three times a day, and each small bottle contains 10 ml Jiu Wei Shuang Jie Kou Fu Ye. A treatment course lasts for 28 days, and the Jiu Wei Shuang Jie Kou Fu Ye takes effect during 3-6 treatment courses. As is shown by the clinical observation on the medicine taking condition of 52 cases of chronic hepatitis patients, the Jiu Wei Shuang Jie Kou Fu Ye is used for treating chronic hepatitis, the significant efficiency is 57.7%, the effective rate is 28.8%, the ineffective rate is 13.5%, the overall effective rate is 86.5%, and the Jiu Wei Shuang Jie Kou Fu Ye is worthy of popularization.
A group of 91 colorectal patients treated in a single institution was involved into the study. Only the patients with tumors located in the rectum or left side colon were included. The term left colon was defined as the left 1/3 of transverse colon and all the colon parts distally from this point. None of the colon cancer patients received preoperative chemotherapy, while 5 of the rectal cancer patients received preoperative radiotherapy and two preoperative radiochemotherapy. There were 42 women and 49 men, the mean age 64,7 (SD - standard deviation 10,2). The bone marrow biopsy was performed on the day of surgery after the induction of general anesthesia from posterior superior iliac spine. The 5ml sample of the bone marrow was collected to plastic tubes containing EthyleneDiamineTetraacetic (EDTA). Patients received postoperative chemotherapy if indicated, regardless of their DTC status. All the patients were followed up at least for 5 years or until death.

The incidence of DTC was not related to the depth of infiltration (T feature) being similar in T1-2 and T4 patients. There was no statistically significant difference between the incidence of DTC in N- and N+ patients. The 5 years survival rate for the DTC patients was 59,5% while for the DTC negative patients was 53%.
PURPOSE:To obtain a therapeutic agent for dysmnesia capable of raising the intracellular calcium level of neurons, enhancing choline acetyltransferase activity and preventing, improving or treating Alzheimer type dysmnesia. CONSTITUTION:A therapeutic agent for dysmnesia containing erythropoietin(EPO) protein which is one kind of cytokinin and a hematopoietic factor, preferably the EPO or EPO mutein protein prepared by a genetic engineering technique as an active ingredient. The above-mentioned therapeutic agent is a preventive, improving or therapeutic agent for Alzheimer type dysmnesia in the dosage form of preferably a direct infusion into intracranial septal areas. The preventive, improving and therapeutic agent acts as a neurotrophic factor for neurons and has the preventive, improving and therapeutic actions on the dysmnesia. Since toxicity is low, the agent can safely be used. Furthermore, although the dose of the above-mentioned active ingredient can suitably be changed according to the extent of damage, it is about 1000-100000 IU at a time for an adult.